Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06207123 | A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) | recruiting | Phase 1 / Phase 2 | 15 | University of ChicagoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07270770 | BY002 IIT Study in R/R Acute Leukemia | recruiting | Phase 1 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07479927 | Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy(PsyCARTkids) | recruiting | N/A | 40 | Hospital Universitario La PazOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03590171 | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | recruiting | Phase 2 | 250 | Charite University, Berlin, GermanyOTHER | 15 | Mar 17, 2026 | clinicaltrials |
| NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation(ACCELERATE) | recruiting | Phase 2 | 358 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06918431 | Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | recruiting | Phase 2 | 53 | City of Hope Medical CenterOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06325280 | Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease | recruiting | — | 20 | University of AlbertaOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06994676 | A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias(CROSSCHECK-001) | recruiting | Phase 1 | 72 | Crossbow Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04644016 | Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | recruiting | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05451979 | HIIT in Pediatric Heart Transplant Recipients (MedBIKE™) | recruiting | N/A | 10 | University of AlbertaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | recruiting | Phase 1 | 420 | Kura Oncology, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06055621 | Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE(VEN-R DASA) | recruiting | Phase 2 | 35 | Institut Paoli-CalmettesOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06557421 | De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients(STOP VEN) | recruiting | Phase 2 | 50 | Institut Paoli-CalmettesOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07470073 | A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults | recruiting | Early Phase 1 | 18 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07471789 | Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). | recruiting | Phase 1 / Phase 2 | 33 | Gyala TherapeuticsINDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03970096 | Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | recruiting | Phase 2 | 120 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | recruiting | Phase 1 | 30 | Andrew E. Place, MDOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05627232 | Tazemetostat and Palbociclib With CPX-351for R/R AML | recruiting | Phase 1 | 24 | Thomas Jefferson UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06867289 | Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring(DINAMO) | recruiting | N/A | 50 | Centre Hospitalier Régional Metz-ThionvilleOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05535855 | UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 | recruiting | Phase 1 | 29 | University of Colorado, DenverOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05679895 | Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL(CARxALL) | recruiting | Phase 1 | 20 | OneChain ImmunotherapeuticsINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05748197 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | recruiting | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | recruiting | Phase 2 | 216 | City of Hope Medical CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06316856 | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies | recruiting | Phase 1 / Phase 2 | 54 | Beijing GoBroad HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06343090 | Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients | recruiting | N/A | 353 | Beijing GoBroad HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06249880 | Pediatric Normative Markerless Movement Analysis | recruiting | — | 40 | MultiCare Health System Research InstituteOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06326008 | Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial | recruiting | Phase 1 | 48 | Beijing GoBroad HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05581030 | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07147621 | Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies(HematoBrain) | recruiting | — | 120 | University Hospital, AngersOTHER_GOV | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05672147 | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06510868 | Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy(MDS & PRRT) | recruiting | — | 45 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06543381 | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06575296 | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07451912 | Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07044544 | Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | recruiting | Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06483906 | Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. | recruiting | Phase 2 | 56 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07283094 | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia(FHD-286) | recruiting | Phase 1 | 33 | Montefiore Medical CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07445438 | Feasibility of a Multi-omics Platform for Hematological Malignancies(FOCUS) | recruiting | N/A | 1,040 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07445984 | Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021) | recruiting | N/A | 250 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04794296 | Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP(LALGFA2019) | recruiting | — | 500 | French Africa Pediatric Oncology GroupOTHER | 3 | Mar 2, 2026 | clinicaltrials |
| NCT06481228 | Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL | recruiting | N/A | 82 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06481241 | Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL | recruiting | N/A | 77 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | recruiting | Phase 3 | 240 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05558124 | CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | recruiting | Phase 1 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06367725 | Pharmacokinetics of Dexamethasone in Childhood ALL and Reduction in Bone Mineral Density | recruiting | — | 100 | University of AarhusOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06511882 | Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | recruiting | Phase 2 | 37 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07441291 | CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT | recruiting | Phase 3 | 70 | Peking University People's HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05580601 | Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 20 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06389305 | CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction | recruiting | N/A | 213 | Beijing GoBroad HospitalOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07422337 | A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab(BOOSTER) | recruiting | — | 300 | Arkansas Children's Hospital Research InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2026source: clinicaltrials